Date Filed | Type | Description |
12/02/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
10/28/2022 |
SC 13D/A
| New Enterprise Associates 16, L.P. reports a 11.6% stake in Akouos, Inc. |
10/11/2022 |
SC 13D
| New Enterprise Associates 16, L.P. reports a 7.3% stake in Allakos Inc. |
05/27/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
05/26/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
04/25/2022 |
SC 13D/A
| New Enterprise Associates 16, L.P. reports a 42.5% stake in Trevi Therapeutics, Inc. |
04/13/2022 |
4
| New Enterprise Associates 16, L.P. (10% Owner) has filed a Form 4 on Trevi Therapeutics, Inc.
Txns:
| Bought 2,631,578 shares
@ $1.9, valued at
$5M
|
|
01/05/2022 |
SC 13D/A
| New Enterprise Associates 16, L.P. has filed a Schedule 13D for Metacrine, Inc. |
12/27/2021 |
4
| New Enterprise Associates 16, L.P. (10% Owner) has filed a Form 4 on Metacrine, Inc.
Txns:
| Sold 37,570 shares
@ $1.321, valued at
$49.6k
Sold 288,768 shares
@ $1.0018, valued at
$289.3k
Sold 170,932 shares
@ $0.9101, valued at
$155.6k
|
|
11/02/2021 |
SC 13D/A
| New Enterprise Associates 16, L.P. reports a 36.1% stake in Trevi Therapeutics, Inc. |
10/19/2021 |
4
| New Enterprise Associates 16, L.P. (10% Owner) has filed a Form 4 on Trevi Therapeutics, Inc.
Txns:
| Bought 1,851,852 shares
@ $0 Bought 1,851,852 options to buy
@ $1.37, valued at
$2.5M
|
|
04/13/2021 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
03/26/2021 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
03/18/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
03/16/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
03/10/2021 |
SC 13D/A
| New Enterprise Associates 16, L.P. has filed a Schedule 13D for Allakos Inc. |
12/07/2020 |
4
| Growth Equity Opportunities V, LLC (10% Owner) has filed a Form 4 on Regulus Therapeutics Inc.
Txns:
| Bought 4,398,602 shares
@ $0.622, valued at
$2.7M
Bought 5,239,254 warrants
@ $0.7464, valued at
$3.9M
Bought 258,707 options to buy
@ $6.22, valued at
$1.6M
|
|
09/28/2020 |
SC 13D
| New Enterprise Associates 16, L.P. reports a 11.8% stake in Metacrine, Inc. |
09/22/2020 |
4
| New Enterprise Associates 16, L.P. (10% Owner) has filed a Form 4 on Metacrine, Inc.
Txns:
| Converted 1,958,333 shares
@ $0 Converted 332,964 shares
@ $0 Bought 769,230 shares
@ $13, valued at
$10M
Converted 1,958,333 convertible preferred
@ $0 Converted 332,964 convertible preferred
@ $0 |
|
09/15/2020 |
3
| New Enterprise Associates 16, L.P. (10% Owner) has filed a Form 3 on Metacrine, Inc. |
08/03/2020 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
07/28/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
07/07/2020 |
SC 13D
| Form SC 13D - General statement of acquisition of beneficial ownership: |
07/01/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
06/25/2020 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
04/16/2020 |
SC 13D/A
| New Enterprise Associates 16, L.P. reports a 33.3% stake in Trevi Therapeutics, Inc. |
04/13/2020 |
4
| New Enterprise Associates 16, L.P. (10% Owner) has filed a Form 4 on Trevi Therapeutics, Inc.
Txns:
| Sold 564 shares
@ $2.66, valued at
$1.5k
Exercised (in-or-at-the-money) 1,500,000 options to buy
@ $0.001, valued at
$1.5k
|
|
02/13/2020 |
SC 13D
| Form SC 13D - General statement of acquisition of beneficial ownership: |
01/29/2020 |
3
| New Enterprise Associates 16, L.P. (10% Owner) has filed a Form 3 on Black Diamond Therapeutics, Inc. |
12/26/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
07/30/2019 |
SC 13D
| New Enterprise Associates 16, L.P. reports a 18.2% stake in Mirum Pharmaceuticals, Inc. |
07/24/2019 |
4
| New Enterprise Associates 16, L.P. (10% Owner) has filed a Form 4 on Mirum Pharmaceuticals, Inc.
Txns:
| Converted 3,736,243 shares
@ $0 Bought 450,000 shares
@ $15, valued at
$6.8M
Converted 29,889,945 preferred shares
@ $0 |
|
07/17/2019 |
3
| New Enterprise Associates 16, L.P. (10% Owner) has filed a Form 3 on Mirum Pharmaceuticals, Inc. |
06/28/2019 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
|